beclometasone/formoterol / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beclometasone/formoterol / Generic mfg.
NCT00910793 / 2008-002391-97: Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients

Completed
4
29
Europe
Inuvair
Wilfried De Backer, UCB Pharma
Asthma
08/10
08/10
FACTO, NCT00901368 / 2008-003740-11: Study (Foster® As Complete Treatment Option)

Completed
4
431
Europe
FOSTER, Seretide
Chiesi Farmaceutici S.p.A.
Asthmatic Patients
09/10
12/10
NCT01466712: Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function

Unknown status
4
20
Europe
Tiotropium + formoterol/beclometasone, Inuvair (B10356), tiotropium + placebo, drug code number B10356
KU Leuven, Chiesi Farmaceutici S.p.A.
COPD, Emphysema, Small Airway Disease
12/14
12/14
2008-005707-26: Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budesonide and formoterol fumarate (Symbicort Turbohaler®). FLEX study (Foster fixed combination on Lung Impedance and Exhaled nitric oXide)A single-centre, randomized, double blind, double-dummy, two-way cross-over, repeated dose study

Completed
4
24
Europe
Foster® 100/6, SYMBICORT® TURBOHALER® 160/4,5, CHF 1535 HFA pMDI, NA, FOSTER®, Symbicort® Turbohaler®, FOSTER®, Symbicort® Turbohaler®
Chiesi Farmaceutici SpA
Bronchial Asthma
 
05/10
2008-002844-40: A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS

Ongoing
4
20
Europe
CHF 718 HFA, CHF 718 HFA, Atimos, Foster, Atimos, Foster
Leiden University Medical Center
astma
 
 
ANDA2, NCT01656005 / 2011-006008-11: Beta Blocker Therapy in Moderate to Severe COPD

Completed
4
18
Europe
Carvedilol, Bisoprolol, Beclometasone/formoterol, Fostair 100/6, Tiotropium, Spiriva 18mcg, Beclometasone, Clenil 200
University of Dundee, Tenovus Scotland
Chronic Obstructive Pulmonary Disease
07/16
07/16
TRIFORCE, NCT05097014 / 2020-004718-36: CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Completed
4
106
Europe
CHF5993, TRIMBOW®, CHF1535, FOSTER®, Matched placebo
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
02/23
02/23
MiSTIC, NCT05018598 / 2021-002391-39: Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA

Active, not recruiting
4
320
Europe
Administration via pressurized metered dose inhaler (pMDI)
Chiesi Farmaceutici S.p.A.
Asthma
04/24
04/24

Download Options